Regulatory approval

Published by the Health Canada. Approved

AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.

This is written in the approval document.

Citation

Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane
HC (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
HC (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals